Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Treasury Shares (2022 - 2025)

Amylyx Pharmaceuticals (AMLX) has 4 years of Treasury Shares data on record, last reported at $2.1 million in Q4 2025.

  • For Q4 2025, Treasury Shares fell 5.58% year-over-year to $2.1 million; the TTM value through Dec 2025 reached $2.1 million, down 5.58%, while the annual FY2025 figure was $2.1 million, 5.58% down from the prior year.
  • Treasury Shares reached $2.1 million in Q4 2025 per AMLX's latest filing, roughly flat from $2.1 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.1 million in Q2 2025 and bottomed at $596709.0 in Q1 2022.
  • Average Treasury Shares over 4 years is $1.6 million, with a median of $1.2 million recorded in 2023.
  • Peak YoY movement for Treasury Shares: soared 174.08% in 2024, then tumbled 33.58% in 2025.
  • A 4-year view of Treasury Shares shows it stood at $740297.0 in 2022, then soared by 50.28% to $1.1 million in 2023, then surged by 98.91% to $2.2 million in 2024, then decreased by 5.58% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $2.1 million in Q4 2025, $2.1 million in Q3 2025, and $3.1 million in Q2 2025.